Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
Mancuso
A
A
Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. mancusoan@gmail.com
Sacchetta
S
S
Saletti
P C
PC
Tronconi
C
C
Milesi
L
L
Garassino
M
M
Martelli
O
O
Leone
A
A
Zivi
A
A
Cerbone
L
L
Recine
F
F
Sollami
R
R
Labianca
R
R
Cavalli
F
F
Sternberg
C N
CN
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics; D004720:Endonucleases / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016879:Salvage Therapy; D015996:Survival Rate
D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D011743:Pyrimidines; D012333:RNA, Messenger; C071447:ERCC1 protein, human; D004720:Endonucleases